Acta Med. 2025, 68: 113-122

https://doi.org/10.14712/18059694.2026.1

Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?

Martin ŠimkovičID, Eva Vejražková, Dominika Écsiová, Pavel Vodárek

4th Department of Internal Medicine, University Hospital Hradec Králové, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic

Received January 6, 2026
Accepted January 7, 2026

References

1. Walewska R, Eyre TA, Bloor A, et al. 2025 British Society for Haematology Guideline for the Treatment of Chronic Lymphocytic Leukaemia. Br J Haematol. 2025 Oct 9.
2. Eichhorst B, Ghia P, Niemann CU, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024; 35(9): 762–8. <https://doi.org/10.1016/j.annonc.2024.06.016>
3. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations Driving CLL and Their Evolution in Progression and Relapse. Nature. 2015; 526(7574): 525–30. <https://doi.org/10.1038/nature15395> <PubMed>
4. Damle RN, Wasil T, Fais F, et al. Ig V Gene Mutation Status and CD38 Expression as Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. Blood. 1999; 94(6): 1840–7. <https://doi.org/10.1182/blood.V94.6.1840>
5. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 Induce Apoptosis by Targeting BCL2. Proc Natl Acad Sci USA. 2005; 102(39): 13944–9. <https://doi.org/10.1073/pnas.0506654102> <PubMed>
6. Burger JA, Barr PM, Robak T, et al. Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-up of First-Line Ibrutinib Treatment for CLL/SLL. Blood. 2025 Jul 30.
7. Niemann CU, Munir T, Moreno C, et al. Fixed-Duration Ibrutinib-Venetoclax versus Chlorambucil-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukaemia (GLOW): 4-Year Follow-up from a Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet Oncol. 2023; 24(12): 1423–33. <https://doi.org/10.1016/S1470-2045(23)00452-7>
8. Gambril JA, Ghazi SM, Sansoterra S, et al. Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation. Leukemia. 2024; 38(10): 2141–9. <https://doi.org/10.1038/s41375-024-02334-3> <PubMed>
9. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021 Jul 26.
10. Brown JR, Byrd JC, Ghia P, et al. Cardiovascular Adverse Events in Patients with Chronic Lymphocytic Leukemia Receiving Acalabrutinib Monotherapy: Pooled Analysis of 762 Patients. Haematologica. 2020.
11. Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 6-Year Results of the Randomized Phase 3 CLL14 Study. Blood. 2024 Jul 14.
12. Fürstenau M, Kater AP, Robrecht S, et al. First-Line Venetoclax Combinations versus Chemoimmunotherapy in Fit Patients with Chronic Lymphocytic Leukaemia (GAIA/CLL13): 4-Year Follow-up from a Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet Oncol. 2024; 25(6): 744–59. <https://doi.org/10.1016/S1470-2045(24)00196-7>
13. Kater AP, Harrup RA, Kipps TJ, et al. The MURANO Study: Final Analysis and Retreatment/Crossover Substudy Results of VenR for Patients with Relapsed/Refractory CLL. Blood. 2025 Feb 26.
14. Hallek M. Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy. Am J Hematol. 2025; 100(3): 450–80. <https://doi.org/10.1002/ajh.27546> <PubMed>
15. Špaček M, Šimkovič M, Pospíšilová Š, et al. Recommendations for Chronic Lymphocytic Leukaemia Diagnosis and Therapy. Transfuze Hematol Dnes. 2025; 31(3).
16. Döhner H, Stilgenbauer S, Benner A, et al. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. N Engl J Med. 2000; 343(26): 1910–6. <https://doi.org/10.1056/NEJM200012283432602>
17. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 Are an Independent Predictor of Survival in Chronic Lymphocytic Leukemia. Blood. 2012; 119(2): 521–9. <https://doi.org/10.1182/blood-2011-09-379966> <PubMed>
18. Puente XS, Pinyol M, Quesada V, et al. Whole-Genome Sequencing Identifies Recurrent Mutations in Chronic Lymphocytic Leukaemia. Nature. 2011; 475(7354): 101–5. <https://doi.org/10.1038/nature10113> <PubMed>
19. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. N Engl J Med. 2011; 365(26): 2497–506. <https://doi.org/10.1056/NEJMoa1109016> <PubMed>
20. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The Clinical Significance of NOTCH1 and SF3B1 Mutations in the UK LRF CLL4 Trial. Blood. 2013; 121(3): 468–75. <https://doi.org/10.1182/blood-2012-05-429282>
21. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent Mutations Refine Prognosis in Chronic Lymphocytic Leukemia. Leukemia. 2015; 29(2): 329–36. <https://doi.org/10.1038/leu.2014.196>
22. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results from the CLL8 Trial. Blood. 2014; 123(21): 3247–54. <https://doi.org/10.1182/blood-2014-01-546150>
23. Rossi D, Khiabanian H, Spina V, et al. Clinical Impact of Small TP53 Mutated Subclones in Chronic Lymphocytic Leukemia. Blood. 2014; 123(14): 2139–47. <https://doi.org/10.1182/blood-2013-11-539726> <PubMed>
24. Landau DA, Carter SL, Stojanov P, et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Cell. 2013; 152(4): 714–26. <https://doi.org/10.1016/j.cell.2013.01.019> <PubMed>
25. Nadeu F, Delgado J, Royo C, et al. Clinical Impact of the Subclonal Architecture and Mutational Complexity in Chronic Lymphocytic Leukemia. Leukemia. 2018; 32(3): 645–53. <https://doi.org/10.1038/leu.2017.291> <PubMed>
26. Langerbeins P, Giza A, Robrecht S, et al. Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the Era of Targeted Therapies. Blood. 2024; 143(25): 2588–98. <https://doi.org/10.1182/blood.2023022564>
27. Fischer K, Bahlo J, Fink AM, et al. Long-Term Remissions after FCR Chemoimmunotherapy in Previously Untreated Patients with CLL: Updated Results of the CLL8 Trial. Blood. 2016; 127(2): 208–15. <https://doi.org/10.1182/blood-2015-06-651125>
28. Eichhorst B, Fink AM, Bahlo J, et al. First-Line Chemoimmunotherapy with Bendamustine and Rituximab versus Fludarabine, Cyclophosphamide, and Rituximab in Patients with Advanced Chronic Lymphocytic Leukaemia (CLL10): An International, Open-Label, Randomised, Phase 3, Non-Inferiority Trial. Lancet Oncol. 2016; 17(7): 928–42. <https://doi.org/10.1016/S1470-2045(16)30051-1>
29. Shanafelt TD, Wang XV, Hanson CA, et al. Tolerability and Long-Term Disease Control by IGHV Mutation Status among Patients with CLL on Ibrutinib Arm of E1912. Blood Adv. 2025; 9(1): 224–8. <https://doi.org/10.1182/bloodadvances.2024013474> <PubMed>
30. Shanafelt TD, Wang XV, Hanson CA, et al. Long-Term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial. Blood. 2022; 140(2): 112–20. <https://doi.org/10.1182/blood.2021014960> <PubMed>
31. Moreno C, Greil R, Demirkan F, et al. First-Line Treatment of Chronic Lymphocytic Leukemia with Ibrutinib plus Obinutuzumab versus Chlorambucil plus Obinutuzumab: Final Analysis of the Randomized, Phase III iLLUMINATE Trial. Haematologica. 2022; 107(9): 2108–20. <https://doi.org/10.3324/haematol.2021.279012> <PubMed>
32. Blombery P, Chatzikonstantinou T, Gerousi M, et al. Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia: Current Status and Perspectives for Clinical and Diagnostic Practice. Leukemia. 2025; 39(9): 2049–60. <https://doi.org/10.1038/s41375-025-02662-y> <PubMed>
33. Tam CS, Thompson PA. BTK Inhibitors in CLL: Second Generation Drugs and Beyond. Blood Adv. 2024; 8(5): 1021–32.
34. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without Obinutuzumab versus Chlorambucil and Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukaemia (ELEVATE-TN): A Randomised, Controlled, Phase 3 Trial. Lancet. 2020; 395(10232): 1278–91. <https://doi.org/10.1016/S0140-6736(20)30262-2> <PubMed>
35. Shadman M, Munir T, Robak T, et al. Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA. J Clin Oncol. 2025; 43(7): 780–7. <https://doi.org/10.1200/JCO-24-02265> <PubMed>
36. Wierda WG, Allan JN, Siddiqi T, et al. (a) Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021; 39(34): 3853–65. <https://doi.org/10.1200/JCO.21.00807> <PubMed>
37. Ghia P, Pluta A, Wach M, et al. Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere. 2022; 6(12): e801. <https://doi.org/10.1097/HS9.0000000000000801> <PubMed>
38. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. N Engl J Med. 2014; 371(3): 213–23. <https://doi.org/10.1056/NEJMoa1400376> <PubMed>
39. Munir T, Brown JR, O’Brien S, et al. Final Analysis from RESONATE: Up to Six Years of Follow-up on Ibrutinib in Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Am J Hematol. 2019; 94(12): 1353–63. <https://doi.org/10.1002/ajh.25638> <PubMed>
40. Woyach JA, Jones D, Jurczak W, et al. Mutational Profile of Previously Treated Chronic Lymphocytic Leukemia Patients Progressing on Acalabrutinib or Ibrutinib. Blood. 2024; 144(10): 1061–8. <https://doi.org/10.1182/blood.2023023659> <PubMed>
41. Mashima K, Kuang Y, Fernandes SM, et al. Mutations and Translocations Associated with Venetoclax Resistance in Chronic Lymphocytic Leukemia. Leukemia. 2025; 39(8): 2026–9. <https://doi.org/10.1038/s41375-025-02611-9>
42. Brown JR, Li J, Eichhorst B, et al. Acquired Mutations in Patients with Relapsed/Refractory CLL Who Progressed in the ALPINE Study. Blood Adv. 2025; 9(8): 1918–26. <https://doi.org/10.1182/bloodadvances.2024014206> <PubMed>
43. Brown JR, Eichhorst B, Lamanna N, et al. Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients with R/R CLL/SLL: Final Comparative Analysis of ALPINE. Blood. 2024; 144(26): 2706–17. <https://doi.org/10.1182/blood.2024024667> <PubMed>
44. Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med. 2023; 389(1): 33–44. <https://doi.org/10.1056/NEJMoa2300696>
45. Jones JA, Mato AR, Wierda WG, et al. Venetoclax for Chronic Lymphocytic Leukaemia Progressing after Ibrutinib: An Interim Analysis of a Multicentre, Open-Label, Phase 2 Trial. Lancet Oncol. 2018; 19(1): 65–75. <https://doi.org/10.1016/S1470-2045(17)30909-9> <PubMed>
46. Lew TE, Bennett R, Lin VS, et al. Venetoclax-Rituximab Is Active in Patients with BTKi-Exposed CLL, but Durable Treatment-Free Remissions Are Uncommon. Blood Adv. 2024; 8(6): 1439–43. <https://doi.org/10.1182/bloodadvances.2023011327> <PubMed>
47. Mato AR, Roeker LE, Jacobs R, et al. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res. 2020; 26(14): 3589–96. <https://doi.org/10.1158/1078-0432.CCR-19-3815> <PubMed>
48. Yoon JT, Zhou Y, Mikhaleva M, et al. Characteristics and Outcomes of Patients with Double Refractory and Double Exposed Chronic Lymphocytic Leukemia. Blood Adv. 2025; 9(11): 2808–17. <https://doi.org/10.1182/bloodadvances.2025016006> <PubMed>
49. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene Maraleucel (Liso-Cel) in R/R CLL/SLL: 24-Month Median Follow-Up of TRANSCEND CLL 004. Blood. 2023; 142(Suppl 1): 330. <https://doi.org/10.1182/blood-2023-179529>
50. Danilov A, Fakhri B, Awan FT, et al. Epcoritamab Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from CLL Expansion and Optimization Cohorts of EPCORE CLL-1. Blood. 2024; 144(Abstract 144): 883. <https://doi.org/10.1182/blood-2024-199708>
51. Kater AP, Ye JC, Sandoval-Sus J, et al. Subcutaneous Epcoritamab in Patients with Richter’s Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1). Blood. 2022; 140(Suppl 1): 850–1. <https://doi.org/10.1182/blood-2022-158298>
52. Andersen MA, Niemann CU. Immune Failure, Infection and Survival in Chronic Lymphocytic Leukemia in Denmark. Haematologica. 2018; 103(7): e330. <https://doi.org/10.3324/haematol.2018.197889> <PubMed>
53. Andersen MA, Vojdeman FJ, Klarskov Andersen M, et al. Hypogammaglobulinemia in Newly Diagnosed Chronic Lymphocytic Leukemia Is a Predictor of Early Death. Leuk Lymphoma. 2016; 57(7): 1592–9. <https://doi.org/10.3109/10428194.2016.1142082>
54. Wadhwa PD, Morrison VA. Infectious Complications of Chronic Lymphocytic Leukemia. Semin Oncol. 2006; 33(2): 240–9. <https://doi.org/10.1053/j.seminoncol.2005.12.013>
55. Ishdorj G, Streu E, Lambert P, et al. IgA Levels at Diagnosis Predict for Infections, Time to Treatment, and Survival in Chronic Lymphocytic Leukemia. Blood Adv. 2019; 3(14): 2188–98. <https://doi.org/10.1182/bloodadvances.2018026591> <PubMed>
56. Riches JC, Davies JK, McClanahan F, et al. T Cells from CLL Patients Exhibit Features of T-Cell Exhaustion but Retain Capacity for Cytokine Production. Blood. 2013; 121(9): 1612–21. <https://doi.org/10.1182/blood-2012-09-457531> <PubMed>
57. Nunes C, Wong R, Mason M, et al. Expansion of a CD8(+)PD-1(+) Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression. Clin Cancer Res. 2012; 18(3): 678–87. <https://doi.org/10.1158/1078-0432.CCR-11-2630>
58. Nunes C. Correction: Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression. Clin Cancer Res. 2012; 18(13): 3714. <https://doi.org/10.1158/1078-0432.CCR-11-2630>
59. Roessner PM, Seiffert M. T-Cells in Chronic Lymphocytic Leukemia: Guardians or Drivers of Disease? Leukemia. 2020; 34(8): 2012–24. <https://doi.org/10.1038/s41375-020-0873-2> <PubMed>
60. Tsukada N, Burger JA, Zvaifler NJ, et al. Distinctive Features of ‘Nurselike’ Cells That Differentiate in the Context of Chronic Lymphocytic Leukemia. Blood. 2002; 99(3): 1030–7. <https://doi.org/10.1182/blood.V99.3.1030>
61. Moreira J, Rabe KG, Cerhan JR, et al. Infectious Complications among Individuals with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Cases Compared to Controls. Leukemia. 2013; 27(1): 136–41. <https://doi.org/10.1038/leu.2012.187>
62. Sun C, Tian X, Lee YS, et al. Partial Reconstitution of Humoral Immunity and Fewer Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood. 2015; 126(19): 2213–19. <https://doi.org/10.1182/blood-2015-04-639203> <PubMed>
63. Long M, Beckwith K, Do P, et al. Ibrutinib Treatment Improves T Cell Number and Function in CLL Patients. J Clin Invest. 2017; 127(8): 3052–64. <https://doi.org/10.1172/JCI89756> <PubMed>
64. Burger JA, Ghia P, Rosenwald A, et al. The Microenvironment in Mature B-Cell Malignancies: A Target for New Treatment Strategies. Blood. 2009; 114(16): 3367–75. <https://doi.org/10.1182/blood-2009-06-225326> <PubMed>
65. Sharpe C, Davis J, Mason KD, et al. More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity. Blood. 2018; 132(Suppl 1): 4417. <https://doi.org/10.1182/blood-2018-99-117618>
66. de Weerdt I, Hofland T, de Boer R, et al. Distinct Immune Composition in Lymph Node and Peripheral Blood of CLL Patients Is Reshaped during Venetoclax Treatment. Blood Adv. 2019; 3(17): 2642–52. <https://doi.org/10.1182/bloodadvances.2019000360> <PubMed>
67. Kater AP, Eichhorst B, Owen C, et al. Long‑Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 2022; 140(Suppl 1): 7010–12. <https://doi.org/10.1182/blood-2022-158275>
68. Moreno C, Solman IG, Tam CS, et al. Immune Restoration with Ibrutinib plus Venetoclax in First-Line Chronic Lymphocytic Leukemia: The Phase 2 CAPTIVATE Study. Blood Adv. 2023; 7(18): 5294–5303. <https://doi.org/10.1182/bloodadvances.2023010236> <PubMed>
69. Francis S, Karanth M, Pratt G, et al. The Effect of Immunoglobulin VH Gene Mutation Status and Other Prognostic Factors on the Incidence of Major Infections in Patients with Chronic Lymphocytic Leukemia. Cancer. 2006; 107(5): 1023–33. <https://doi.org/10.1002/cncr.22094>
70. Andersen MA, Rostgaard K, Niemann CU, et al. Antimicrobial Use before Chronic Lymphocytic Leukemia: A Retrospective Cohort Study. Leukemia. 2021; 35(3): 747–51. <https://doi.org/10.1038/s41375-020-0980-0>
71. Varughese T, Taur Y, Cohen N, et al. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. Clin Infect Dis. 2018; 67(5): 687–92. <https://doi.org/10.1093/cid/ciy175> <PubMed>
72. Coutré SE, Barrientos JC, Brown JR, et al. Management of Adverse Events Associated with Idelalisib Treatment: Expert Panel Opinion. Leuk Lymphoma. 2015; 56(10): 2779–86. <https://doi.org/10.3109/10428194.2015.1022770> <PubMed>
73. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. Blood. 2021; 137(23): 3165–73. <https://doi.org/10.1182/blood.2021011568> <PubMed>
74. Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID‑19 Severity and Mortality in Patients with Chronic Lymphocytic Leukemia: A Joint Study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020; 34(9): 2354–63. <https://doi.org/10.1038/s41375-020-0959-x> <PubMed>
75. Šimkovič M, Turcsányi P, Špaček M, et al. COVID‑19 in Patients with Chronic Lymphocytic Leukemia: A Multicenter Analysis by the Czech CLL Study Group. Ann Hematol. 2023; 102(4): 811–17. <https://doi.org/10.1007/s00277-023-05147-z> <PubMed>
76. Campanella A, Capasso A, Heltai S, et al. Additional Booster Doses in Patients with Chronic Lymphocytic Leukemia Induce Humoral and Cellular Immune Responses to SARS‑CoV‑2 Similar to Natural Infection Regardless Ongoing Treatments. Am J Hematol. 2024; 99(4): 745–50. <https://doi.org/10.1002/ajh.27218>
77. Chatzikonstantinou T, Scarfò L, Karakatsoulis G, et al. Other Malignancies in the History of CLL: An International Multicenter Study Conducted by ERIC, the European Research Initiative on CLL, in HARMONY. eClinicalMedicine. 2023; 65: 102307. <https://doi.org/10.1016/j.eclinm.2023.102307> <PubMed>
78. Tsimberidou AM, Wen S, McLaughlin P, et al. Other Malignancies in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma. J Clin Oncol. 2009; 27(6): 904–10. <https://doi.org/10.1200/JCO.2008.17.5398> <PubMed>
79. Wierda WG, Allan JN, Siddiqi T, et al. (b) Ibrutinib Plus Venetoclax for First‑Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021; 39(34): 3853–65. <https://doi.org/10.1200/JCO.21.00807> <PubMed>
80. Kater AP, Owen C, Moreno C, et al. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. NEJM Evid. 2022; 1(7): EVIDoa2200006. <https://doi.org/10.1056/EVIDoa2200006>
81. Munir T, Girvan S, Cairns DA, et al. Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2025 Jun 15.
82. Ryan CE, Davids MS, Hermann R, et al. MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Future Oncol. 2022; 18(33): 3689–99. <https://doi.org/10.2217/fon-2022-0456>
83. Casan JML, Seymour JF. Degraders Upgraded: The Rise of PROTACs in Hematological Malignancies. Blood. 2024; 143(13): 1218–30. <https://doi.org/10.1182/blood.2023022993>
84. Zhong G, Kong R, Feng S, et al. Targeted Protein Degradation in Hematologic Malignancies: Latest Updates from the 2023 ASH Annual Meeting. J Hematol Oncol. 2024; 17(1): 14. <https://doi.org/10.1186/s13045-024-01533-w> <PubMed>
85. Liu J, Li S, Wang Q, et al. Sonrotoclax Overcomes BCL2 G101V Mutation-Induced Venetoclax Resistance in Preclinical Models of Hematologic Malignancy. Blood. 2024; 144(3): 1825–36. <https://doi.org/10.1182/blood.2023019706> <PubMed>
86. Zhou K, Sun M, Wei X, et al. Updated Efficacy and Safety Results of Lisaftoclax (APG‑2575) in Patients with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials. Blood. 2023; 142(Suppl 1): 1900. <https://doi.org/10.1182/blood-2023-183071>
87. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene Maraleucel in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma (TRANSCEND CLL 004): A Multicentre, Open‑Label, Single‑Arm, Phase 1–2 Study. Lancet. 2023; 402(10402): 641–54. <https://doi.org/10.1016/S0140-6736(23)01052-8> <PubMed>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive